Analysen von Michael J. Yee
| 28.02.12 | Human Genome Sciences sector perform | RBC Capital Markets | |
| 27.02.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 24.02.12 | Celgene outperform | RBC Capital Markets | |
| 24.02.12 | Dendreon sector perform | RBC Capital Markets | |
| 23.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 23.02.12 | Human Genome Sciences sector perform | RBC Capital Markets | |
| 17.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 17.02.12 | Biogen outperform | RBC Capital Markets | |
|
Werbung
|
|||
| 16.02.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 16.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 13.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 09.02.12 | Elan outperform | RBC Capital Markets | |
| 09.02.12 | InterMune outperform | RBC Capital Markets | |
| 06.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 02.02.12 | Elan outperform | RBC Capital Markets | |
| 02.02.12 | Biogen outperform | RBC Capital Markets | |
| 30.01.12 | Amgen outperform | RBC Capital Markets | |
| 26.01.12 | Myriad Genetics outperform | RBC Capital Markets | |
| 25.01.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 23.01.12 | Biogen outperform | RBC Capital Markets | |
| 23.01.12 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 20.01.12 | Gilead Sciences outperform | RBC Capital Markets | |
| 19.01.12 | Xoma outperform | RBC Capital Markets | |
| 19.01.12 | Amgen outperform | RBC Capital Markets | |
| 19.01.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
| 18.01.12 | Celgene outperform | RBC Capital Markets | |
| 18.01.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 13.01.12 | Human Genome Sciences outperform | RBC Capital Markets | |
| 11.01.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 11.01.12 | Dendreon sector perform | RBC Capital Markets | |
| 12.12.11 | Celgene outperform | RBC Capital Markets | |
| 08.12.11 | ImmunoGen outperform | RBC Capital Markets | |
| 08.12.11 | Amgen outperform | RBC Capital Markets | |
| 06.12.11 | Elan outperform | RBC Capital Markets | |
| 06.12.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 01.12.11 | Celgene outperform | RBC Capital Markets | |
| 28.11.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 21.11.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 16.11.11 | Gilead Sciences outperform | RBC Capital Markets | |
| 15.11.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
| 15.11.11 | Elan outperform | RBC Capital Markets | |
| 14.11.11 | Biogen outperform | RBC Capital Markets | |
| 07.11.11 | Vertex Pharmaceuticals sector perform | RBC Capital Markets | |
| 03.11.11 | Celgene outperform | RBC Capital Markets | |
| 03.11.11 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 03.11.11 | Dendreon sector perform | RBC Capital Markets | |
| 02.11.11 | Auxilium Pharmaceuticals sector perform | RBC Capital Markets | |
| 28.10.11 | Human Genome Sciences outperform | RBC Capital Markets | |
| 26.10.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
| 26.10.11 | Amgen outperform | RBC Capital Markets | |